Kanova Biopharma was founded by a world-renowned immunologist in Nov. 2015. Based on its cutting-edge research in immunology, Kanova focuses on developing first-in-class therapeutic antibodies or innovative combination therapies to treat cancer and autoimmune diseases.
“Innovation, precision, quality and focus” is the core value of our company. Through our internal research and external collaboration, we aim to accelerate the R&D process of innovative antibody medicines. We root in China with the global vision to discover and develop novel treatments for cancer and autoimmune diseases.
The company has developed a rich pipeline in immuno-oncology and autoimmune diseases based on its proprietary technology platforms in the past five years. These products will help to address the rapidly growing, unmet medical needs in China and around the world.